Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis
BackgroundExpanding antiviral therapy to benefit more populations and optimizing treatment to improve prognoses are two main objectives in current guidelines on antiviral therapy. However, the guidelines do not recommend antiviral therapy for inactive hepatitis B surface antigen (HBsAg) carriers (IH...
Guardado en:
Autores principales: | Aixin Song, Xiao Lin, Junfeng Lu, Shan Ren, Zhenhuan Cao, Sujun Zheng, Zhongjie Hu, Hong Li, Chengli Shen, Xinyue Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5696643232e8487ab9c96bbb62fb2051 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prediction for HBsAg seroconversion in children with chronic hepatitis B
por: Yan-Wei Zhong, et al.
Publicado: (2021) -
The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing
por: Ying Wang, et al.
Publicado: (2021) -
Analysis of the Physicochemical Properties, Replication and Pathophysiology of a Massively Glycosylated Hepatitis B Virus HBsAg Escape Mutant
por: Md. Golzar Hossain, et al.
Publicado: (2021) -
Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Sheikh Mohammad Fazle Akbar, et al.
Publicado: (2021) -
Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers
por: Mary C. Kuhns, et al.
Publicado: (2021)